Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 M4XpWWN6fG:2b4jpZ4l1gSCDc4PhfS=> Mm\rNQKBmzF4MNMg{txO M2P2dFQ5yqCq NWPtXIlJUUN3ME21MljDqMLzwrCwMlUh|ryP MmD5NlY1PzR4OUO=
CaES-17 MojzR5l1d3SxeHnjbZR6KEG|c3H5 NYHKUYlzOOLCk{G2NOKh|ryP NET5TnA1QMLiaB?= MYjJR|UxRTVwNdMgxtHDqDBwMjFOwG0> NEfmSI4zPjR5NE[5Ny=>
SW480 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT2OFghcMLi NYnMNXZYUUN3ME2xMlg4KM7:TR?= MmrlNlYzPjl5NUm=
HCT116 NEPPcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zZTVQ5KGkEoB?= MmKwTWM2OD1zMT64OkDPxE1? NELnUI8zPjJ4OUe1PS=>
LoVo NUPhfXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[3OFghcMLi NGXKNZlKSzVyPUm0Mlg{KM7:TR?= M2LvOlI3OjZ7N{W5
SK-BR-3 M3nibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNzLkCgxtEhOC5zIN88US=> NFHzTHEzPjJzMUW5NS=>
MCF-7 M2m1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DjcWlEPTB;MUWuOEDDuSByLkOg{txO NYTlTmNVOjZ{MUG1PVE>
MDA-MB-231 NUL2XJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJ|LkGgxtEhOC5zIN88US=> M3nRXVI3OjFzNUmx
HCT116 p53+/+ MmO4SpVv[3Srb36gRZN{[Xl? M1\3[FEwPSEQvF2= MYiyOE81QCCq M{DM[4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= MUmyOlIxQDV{Mx?=
LoVo  NG\tVWZHfW6ldHnvckBCe3OjeR?= NEPtO|AyNzVizszN Mmn6NlQwPDhiaB?= MXvpcoR2[2W|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q NU\6R|hxOjZ{MEi1NlM>
SNU-398 NHi4UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X3OmlEPTB;Nj61xsDDucLiMT6xJO69VQ>? M4j3fFI3OTZyNEK5
Hep-G2 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF|LkJCpOKyyqBzLk[g{txO NXrHTXZnOjZzNkC0Nlk>
SNU-475 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHhfmhKSzVy78{eN|Ah|ryP NXLFXY1pOjZzNkC0Nlk>
SNU-387 M4ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjsTWM2OD1{NdMgxtHDqDJwNzFOwG0> MWOyOlE3ODR{OR?=
HT29 NGPqOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\FTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? NWK5[GV2OjZzNEi1PVY>
HCT116 M{LSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfseGhKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= NEXZO2MzPjF2OEW5Oi=>
PA-1 M{W0UmNmdGxiVnnhZoltcXS7IFHzd4F6 M2XPelAuOjBizszN NXLqNmZXOjRxNEigbC=> NH7ORldqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXrQbY84OjZzM{i2O|E>
OVCAR-5 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF;OfHExNTZyIN88US=> MWeyOE81QC95MjDo MnHubY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NYK1TlY1OjZzM{i2O|E>
SK-OV-3 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoWwNE0yODBizszN NFnnd2szPC92OD:3NkBp MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NV7xU2dWOjZzM{i2O|E>
PA-1 NETVPGdHfW6ldHnvckBCe3OjeR?= MonENVAh|ryPwrC= M3vaflI1cA>? NInLNFh1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NYTofFY{OjZzM{i2O|E>
OVCAR-5 M3T6NGZ2dmO2aX;uJGF{e2G7 MXyzNEDPxE1? NXjxWVY2PDiq MnzleJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz NX;PVnBZOjZzM{i2O|E>
SK-OV-3 NXXwblU1TnWwY4Tpc44hSXO|YYm= M37Y[lUxKM7:TR?= NXH1V|RVQTZiaB?= NFfEUVJ1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NWflXndJOjZzM{i2O|E>
PA-1 MXfGeY5kfGmxbjDBd5NigQ>? MYCxNEDPxE4EoB?= MVi0PIg> Mn\6eZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ NFX2ZYIzPjF|OE[3NS=>
OVCAR-5 MVzGeY5kfGmxbjDBd5NigQ>? M4e0ZVMxKM7:TR?= MWW0PIg> NHHVU2N2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NGHsdmIzPjF|OE[3NS=>
SK-OV-3 M3nEOGZ2dmO2aX;uJGF{e2G7 MmPWOVAh|ryP MmjlPVYhcA>? MXX1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> NHnBcIszPjF|OE[3NS=>
PA-1 MoDFSpVv[3Srb36gRZN{[Xl? NWXkXolCOTBizszNxsA> MUKyOIg> MUTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NWTLdWJVOjZzM{i2O|E>
OVCAR-5 M4[we2Z2dmO2aX;uJGF{e2G7 MY[yNEDPxE4EoB?= NFzOSG0zPGh? MoD5dJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= NV;McId2OjZzM{i2O|E>
SK-OV-3 NH7BU5RHfW6ldHnvckBCe3OjeR?= NYDONHJQPTBizszNxsA> MkTQOFghcMLi MY\wdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NX\lcYpkOjZzM{i2O|E>
CT26  NWXJXHZ4TnWwY4Tpc44hSXO|YYm= NGrmSm41KG2P NGPj[3M1QCCqwrC= NFuwXoFqdmS3Y3XzJIF2fG:yaHHnfS=> NEXle40zPjF|N{CxNi=>
CT26  MVvGeY5kfGmxbjDBd5NigQ>? NEjzWHM1KG2P NU\obWI3PDhiaNMg MUXpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Yx{KG:oIHH1eI9xcGGpeT3y[YxifGWmIIDyc5RmcW6|LDDzeYNpKGG|IFzDN{1KUSxiQnXjcIlvOSCjbnSgRXRIPQ>? NVfN[HdTOjZzM{ewNVI>
CT26  NWPkR484S2WubDDWbYFjcWyrdImgRZN{[Xl? NYC4XWk5PCCvTR?= MmfqOFghcMLi MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? NX3aNIVXOjZzM{ewNVI>
BE MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDkbGdKSzVyPUOuN|Mh|ryP NHnORokzPjB{M{C4OS=>
Colo205 M{Tzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz5TWM2OD1|LkOzJO69VQ>? NHPaOFIzPjB{M{C4OS=>
DLD1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C2TWlEPTB;Mj6wNUDPxE1? Mo[1NlYxOjNyOEW=
HT29 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwNkmg{txO NET2V2EzPjB{M{C4OS=>
HCT15 NYPBWXZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0WWlEPTB;MT60N{DPxE1? M{O5Z|I3ODJ|MEi1
HCT116 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jEUWlEPTB;MT6wOEDPxE1? NWPF[YtMOjZyMkOwPFU>
HCT116p53- NIXrOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jabmlEPTB;MT6wPEDPxE1? M3u2OVI3ODJ|MEi1
KM12 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\TdXgzUUN3ME20MlM4KM7:TR?= NFHIUYwzPjB{M{C4OS=>
LoVo NGG5XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H4TWlEPTB;MT6yJO69VQ>? M1fMSlI3ODJ|MEi1
RKO NUXGb49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC3TWM2OD1zLkKzJO69VQ>? NXvvdVFQOjZyMkOwPFU>
SW480 M3;2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjdWx{UUN3ME2yMlg3KM7:TR?= MVuyOlAzOzB6NR?=
SW620 NIXnN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D2fGlEPTB;Mz62PEDPxE1? NGWwN20zPjB{M{C4OS=>
MC38 NV;EVm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0NnQxUUN3ME2yN{DPxE1iwsGgNi=> NVjHfm9mOjZyMESwPFQ>
HT29 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Ta[mlEPTB;NkOg{txOKMLzIEG4 M1fQbFI3ODB2MEi0
DLD-1 NH3HdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN{LkKg{txO NX7QZY5jOjZyMEOwPFU>
HT-29 NXHWemdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHiTWM2OD1|NT62JO69VQ>? NFHKZVMzPjByM{C4OS=>
SiHa NIfDOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\rW2lEPTB;MD64JOKyKDBwMTFOwG0> MYiyOVgxOTByNx?=
S3 M3jJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrUW2J4UUN3ME21N{42KMLzIEGuOUDPxE1? NHfBO2gzPThyMUCwOy=>
AGS NGKyR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFyLk[g{txO M2LBUVI2Pzh7MEW3
MKN-45 M1LzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1zND6wJO69VQ>? MXuyOVc5QTB3Nx?=
TMK-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYZ4R1UUN3ME2yNk43KM7:TR?= MYKyOVc5QTB3Nx?=
SCM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3WY5KSzVyPUG3MlUh|ryP M4ThfVI2Pzh7MEW3
HCT-15 NIHmPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpdHBKSzVyPUiuOlQh|ryP NGDzPGozPTd4MUS3PS=>
DiFi MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFyLkm1JO69VQ>? NHfoW5ozPTd4MUS3PS=>
DLD-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiyTWM2OD16Lk[1JO69VQ>? NEXLfHozPTd4MUS3PS=>
COLO-320DM NXTSWpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXNPZFKSzVyPUWuN|gh|ryP MlnnNlU4PjF2N{m=
SNU-175 NIX1ZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH0Wpo2UUN3ME2xMlUyKM7:TR?= NF;WZXIzPTd4MUS3PS=>
HT-29 NWTOfWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nLS2lEPTB;NT6yNkDPxE1? M4jyUVI2PzZzNEe5
SW620 MmnNSpVv[3Srb36gRZN{[Xl? NILmTHMyOOLCidM1[{9udA>? NGPIT|UzPOLCiXi= NWf2OZZlcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= MXuyOVc1QTR{MB?=
SW480 Mm\WSpVv[3Srb36gRZN{[Xl? M4rvWVEx6oDLwsXnM41t M4fkZlI16oDLaB?= NIDJOI5qdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w NWnxOVZJOjV5NEm0NlA>
SW620 NWX0NGs6TnWwY4Tpc44hSXO|YYm= MU[xNQKBkcL3Zz;tcC=> MWCyOQKBkWh? NXHVNFJJ\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NW[4bHdUOjV5NEm0NlA>
SW480 NYLxW21PTnWwY4Tpc44hSXO|YYm= M4XFNVEx6oDLwsXnM41t NF7RUHAzPOLCiXi= MoK3[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 MWCyOVc1QTR{MB?=
A549 NWDzXFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLId5RKSzVyPUWuPEDDuSByLk[g{txO NHn0ZnkzPTZ{NUK0Ny=>
A549/CDDP MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofXTWM2OD1zOD62JOKyKDFwMjFOwG0> NVHOPW9{OjV4MkWyOFM>
Panc-1 NWTIdFNkS2WubDDWbYFjcWyrdImgRZN{[Xl? NVPFdVlLOjVxNUCg{txO NYPmWFBJOjRxNEigbC=> NFrPTWRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MYKyOVQ1PDlzNB?=
MIAPaCa-2 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2jkU|I2NzVyIN88US=> MYCyOE81QCCq M1;YeolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M4PtVlI2PDR2OUG0
SW1990 MoL1R4VtdCCYaXHibYxqfHliQYPzZZk> M4SyTlI2NzVyIN88US=> NF\zTVUzPC92ODDo MWPpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MVeyOVQ1PDlzNB?=
HPDE MnX3R4VtdCCYaXHibYxqfHliQYPzZZk> M4[5XFI2NzVyIN88US=> MVGyOE81QCCq MlT6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NIq4SlEzPTR2NEmxOC=>
Panc-1 MVrBdI9xfG:|aYOgRZN{[Xl? NVPLVnJVOjYkgJpCuW0> Mm\mNlQhcA>? MY\pcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MoDQNlU1PDR7MUS=
MIAPaCa-2 M4rrU2Fxd3C2b4Ppd{BCe3OjeR?= NEXSfXMzPeLCidM1US=> MW[yOEBp NXfvXYwxcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MUeyOVQ1PDlzNB?=
Panc-1 MlH2SpVv[3Srb36gRZN{[Xl? M4TpSFI26oDLwsXN M1zkOVI1NzR6IHi= NH3DS5ZqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> MnToNlU1PDR7MUS=
MIAPaCa-2 M1vsdmZ2dmO2aX;uJGF{e2G7 MmmwNlXjiIoEtV2= M{XMdFI1NzR6IHi= NIrDeYFqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> Ml7JNlU1PDR7MUS=
SW480 NXv3VFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S0WFczKGkEoB?= MUPJR|UxRTFyLkhCtVIvOjZiwsXnM41N Mn35NlU{PjB4M{G=
HCT116  Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2O|IhcMLi M3zvXGlEPTB;Nj6yN:KyOC55NTFCuYcwdUx? MUeyOVM3ODZ|MR?=
COC1 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[2TWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP NInHUJAzPTNyN{S0PC=>
SGC7901 NGH3UppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? M2DtV|I2OzB5NES4
A549 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvmZWh1UUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=> NVLOUZlQOjV|MEe0OFg>
HepG2 NFHYWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS1TWM2OD1zND6yOOKhyrIEoEGuPFIh|ryP MXOyOVMxPzR2OB?=
MCF-7 NELzS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? MnTsNlU{ODd2NEi=
HCT-116 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCTWM2OD14LkK0xsDDucLiMj65O{DPxE1? M2W2[VI2OzB5NES4
HT-29 NV;VbGJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TYfWlEPTB-NUCg{txO MlXsNlU{ODd2NEi=
HEK293 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRThwOENCpOKyyqB3LkW5JO69VQ>? MmfvNlU{ODd2NEi=
HUVEC M4fNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vnS2lEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= M3nWWlI2OzB5NES4
SW480 NYHYeoZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK4NeKh|ryP NFHw[VkxNTd{IHi= MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXfwepRrOjR7OUe0OVE>
HT-29 NXz2R21xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rtSFHDqM7:TR?= NUH3VmZlOC15MjDo M4KyOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NEC3bXczPDl7N{S1NS=>
HCT116 MXzGeY5kfGmxbjDBd5NigQ>? NFjnNVkzNzViwsXN MUOyOE81QCCq NI\sZoN{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> NIL3bIUzPDd4MUSxNS=>
SW480  NH;2d5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWe0PEBpyqB? Ml;LTWM2OD1{MD64JJVoN22O NXzE[npPOjR5MkC2O|U>
SW620 NWLJUWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0cFExNTdyIH3nM2w> MoOwNlQwPDhxN{KgbC=> NIryeIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MU[yOFY1PjNyNR?=
Caco2  MlzqSpVv[3Srb36gRZN{[Xl? NV73PZV2OzEEoN88US=> NEjaRXMzPCCq MWrEUXNQ MVnpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> M2[2ZlI1PTV4NEG1
Caco2  NVLKO2U5TnWwY4Tpc44hSXO|YYm= NFXIWGw{NzFyL{OwJO69VQ>? NELYUZIyPiCq MlLLSG1UVw>? NXHEbGhHcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? NGrGfHQzPDV3NkSxOS=>
Caco2 MkXsSpVv[3Srb36gRZN{[Xl? NH3XcmM{OC9zMEFCpO69VQ>? M2jmS|E3yqCq M3zvUWROW09? MVLhZ5RqfmG2ZYOgUpJnOg>? NVjN[W9xOjR3NU[0NVU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
temperature in solvent (should be freshly prepared each time)
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04003792 Not yet recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 2020 Phase 2
NCT03872908 Not yet recruiting Device: Chilled gloves|Device: Surgical gloves Breast Cancer|Colorectal Cancer Centre Leon Berard June 15 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID